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Astrocytes play an essential role in supporting brain functions in physiological and
pathological states. Modulation of their pathophysiological responses have beneficial
actions on nerve tissue injured by brain insults and neurodegenerative diseases,
therefore astrocytes are recognized as promising targets for neuroprotective drugs.
Recent investigations have identified several astrocytic mechanisms for modulating
synaptic transmission and neural plasticity. These include altered expression of
transporters for neurotransmitters, release of gliotransmitters and neurotrophic factors,
and intercellular communication through gap junctions. Investigation of patients
with mental disorders shows morphological and functional alterations in astrocytes.
According to these observations, manipulation of astrocytic function by gene mutation
and pharmacological tools reproduce mental disorder-like behavior in experimental
animals. Some drugs clinically used for mental disorders affect astrocyte function.
As experimental evidence shows their role in the pathogenesis of mental disorders,
astrocytes have gained much attention as drug targets for mental disorders. In
this paper, I review functional alterations of astrocytes in several mental disorders
including schizophrenia, mood disorder, drug dependence, and neurodevelopmental
disorders. The pharmacological significance of astrocytes in mental disorders is also
discussed.
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Introduction
Astrocytes are the most numerous glial cell in the brain and play an essential role in
maintaining efficient neurotransmission through the supply of energy metabolites, turnover of
neurotransmitters, and establishment of the blood–brain barrier. In earlier studies, astrocytes
were not thought to be actively involved in synaptic transmission, but this perception
was revised when astrocytes were shown to express receptors for most neurotransmitters,
and by which, astrocytic actions are regulated in response to receptor activation. Recent
Abbreviations: L-Glu, L-glutamate; D-Ser, D-serine; GS, glutamine synthetase; GFAP, glial fibrillary acidic protein;
BDNF, brain-derived neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor; SR, serine racemase;
DAAO, D-amino acid oxidase; SVZ, sub-ventricular zone; bFGF, basic fibroblast growth factor; CX43, connexin-
43; AQP4, aquaporin-4; MDD, major depressive disorder; NAcc, nucleus accumbens; VTA, ventral tegmental area;
CPP, conditioned place preference; FXS, fragile X syndrome; MeCP2, methyl-CpG-binding protein 2; FMRP, fragile
X mental retardation 1 protein.
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studies have confirmed that astrocytes are more actively involved
in synaptic transmission than previously predicted (Perea
et al., 2009). Astrocytic mechanisms that regulate synaptic
transmission include release of astrocyte-derived neuroactive
substances and dynamic regulation of neurotransmitter turnover
in response to nerve excitation. Moreover, accumulating
evidence has revealed specialized actions of astrocytes in
the injured brain. One well-studied feature of astrocytes in
neuropathological conditions (including acute brain insults and
neurodegenerative diseases) is their phenotypic conversion to
reactive astrocytes. Following phenotypic conversion, astrocytes
function is altered to affect viability and repair of damaged
nerve tissue (Sofroniew, 2009; Buffo et al., 2010; Koyama,
2014). Supported by these findings, modulation of astrocytic
pathophysiological function was predicted to have beneficial
actions on protection and repair of injured nerve tissue.
Subsequent experiments demonstrated the effectiveness of this
strategy using neuroprotective drugs (Acarin et al., 2001; Cifra
et al., 2011; Tsuda et al., 2011; Carbone et al., 2012), and
the pharmacological significance of astrocytes as a drug target
for acute brain insults and neurodegenerative diseases is now
accepted.
Dysfunction of monoamine- or L-glutamate (L-Glu)-
mediated synaptic transmission in particular brain regions
is known to be a primary pathogenic cause of many mental
disorders (Herberg and Rose, 1990; Lee et al., 2007; Laruelle,
2014; Perez and Lodge, 2014). Prompted by the concept that
astrocytes are more actively involved in synaptic transmission,
many studies have been carried out to relate astrocyte
dysfunction with mental disorders. Nervous tissue dysplasia
during embryonic and postnatal brain development has also
been suggested to induce mental disorders in adults. Although
neuronal degeneration is not a common pathological feature
in mental disorder patients, morphological and functional
observations reveal alterations in astrocyte density and gene
expression in several disorders (Cotter et al., 2002; Stockmeier
et al., 2004; Choudary et al., 2005; Madeira et al., 2008; Habl
et al., 2009; Beardsley and Hauser, 2014). Moreover, many
observations have shown that modulation of astrocyte function
using gene manipulation and pharmacological tools affects
mental disorder-like behavior in experimental animals (Ballas
et al., 2009; Basu et al., 2009; Labrie et al., 2010; Sun et al.,
2012; Yang et al., 2012; Kong et al., 2014). Additionally, studies
on the therapeutic mechanisms of drugs currently used to
treat mental disorders found that their beneficial effects are
mediated via astrocytic mechanisms (Table 1). From these
findings, astrocytes were suggested to play an important role
in the etiology of mental disorders. In the present clinical field,
several types of effective drugs are used for care of patients
with mental disorders. However, further development of
psychiatric drugs will be required. Thus, the use of astrocytic cell
pathways was proposed as a novel strategy in mental disorder
etiology, as well as in the mechanisms of neuroprotective
drugs.
This paper reviews recent studies on the possible roles
of astrocytes in the pathogenesis of mental disorders i.e.,
schizophrenia, mood disorders, drug dependence, and mental
retardation (Rett syndrome and fragile X syndrome, FXS). The
pharmacological significance of astrocytes as drug targets for
mental disorders is also discussed.
Novel Concepts of Astrocyte Function
Astrocytes are known to play a supporting role in synaptic
transmission including maintenance of the ionic balance in
extracellular fluid, supply of energy metabolites to neurons, and
reducing transmitters released into the synaptic cleft (Parpura
et al., 2012). To undertake these supporting roles, astrocytes have
many specific transporters and neurotransmitter metabolizing
enzymes. During regulation of synaptic transmission by L-Glu,
astrocytes take up synaptic L-Glu through highly expressed
excitatory amino acid transporters (EAAT-1 and EAAT-2).
Subsequently, L-Glu is metabolized to L-glutamine by an
astrocyte-specific enzyme, glutamine synthetase (GS). Release of
astrocytic L-glutamine is used as a neuronal L-Glu precursor,
and this interplay between neurons and astrocytes is known
as the glutamine cycle. Specific transporters and metabolizing
enzymes for other neurotransmitters are also expressed in
astrocytes. Expression levels of astrocytic transporters and
metabolizing enzymes are not static, but are dynamically
regulated in response to synaptic activity. This enables
astrocytes to effectively support synaptic transmission. Aside
from their supporting role, the concept that astrocytes are
more actively involved in synaptic transmission is being
recognized. This concept involves the ‘‘tripartite synapse’’,
with astrocytes surrounding the synaptic cleft as an essential
component of the synapse, as well as pre- and post-
synaptic neurons, and with part of the pre-synaptic signal
circumvented via astrocytes to modulate the direct signal
to the post-synaptic neuron (Perea et al., 2009). Evidence
to support this includes the discovery of ‘‘gliotransmitters’’.
The term ‘‘gliotransmitter’’ is used to describe neuroactive
substances released from astrocytes in response to a pre-
synaptic signal. Astrocytes excited by L-Glu and adenosine
triphosphate (ATP), release L-Glu, ATP, adenosine, D-serine
(D-Ser), and eicosanoids in a Ca2+ dependent mechanism.
Because of this excitation-induced release and modulatory
action on synaptic transmission, these substances are thought
to be putative gliotransmitters (Araque et al., 2014). However,
regulation of synaptic transmission by gliotransmitters is
still controversial in physiological states. While release of
gliotransmitters is stimulated in a Ca2+-dependent manner,
experimental manipulation of increased astrocytic Ca2+ failed
to affect excitatory synaptic activity in the hippocampus (Fiacco
et al., 2007; Petravicz et al., 2008). Moreover, increased astrocytic
Ca2+ levels in response to pre-synaptic activations were obtained
after excitation of post-synaptic neurons (Agulhon et al.,
2012). From these findings, Agulhon et al. (2012) proposed
that the gliotransmitter role is less significant in physiological
states.
In pathological states, astrocyte function is remarkably
altered. Specifically, astrocytes are converted to a reactive
phenotype in response to brain injury, which is characterized
by cell body hypertrophy and increased expression of
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TABLE 1 | Drugs showing therapeutic effects on mental disorders by modulation of astrocytic functions.
Drugs Actions on astrocytes Mental disorder Reference
ALX5497,
NEPS
Inhibition of D-Ser uptake Schizophrenia Lipina et al. (2005)
Karasawa et al. (2008)
Kawaura et al. (2014)
Compound 8,
CBIO,
AS05728
Inhibition of DAAO Schizophrenia Adage et al. (2008)
Hashimoto et al. (2009)
Smith et al. (2009)
Clozapine Stimulation of D-Ser release Schizophrenia Tanahashi et al. (2012)
Riluzole Increases in L-Glu transport Depression Banasr et al. (2010)
Desipramine, Fluoxtine, Mianserin, Chromipramine,
Paroxetine
Productions of neurotrophic factors Depression Hisaoka et al. (2001)
Mallei et al. (2002)
Bachis et al. (2008)
Allaman et al. (2011)
Liu et al. (2012)
Kittel-Schneider et al. (2012)
Amitriptyrine,
Fluoxetine,
Duloxetine
Increases in CX43 expression Depression Sun et al. (2012)
Morioka et al. (2014)
MS-153 Increases in L-Glu transport Drug dependence Nakagawa et al. (2005)
Cabergoline Production of GDNF Drug dependence Ohta et al. (2003, 2004)
Fenobam,
AFQ056
mGluR5 antagonism Fragile X syndrome Levenga et al. (2011)
Vinueza Veloz et al. (2012)
glial fibrillary acidic protein (GFAP), an astrocyte-specific
intermediate filament protein (Sofroniew, 2009; Koyama, 2014).
Phenotypic conversion to reactive astrocytes is accompanied
by altered expression of various functional molecules, such
as transporters and neurotransmitter metabolizing enzymes
(Buffo et al., 2010). Altered activities of these astrocytic
molecules may result in disturbed synaptic transmission
and aggravate excitoxicity-induced nerve injury. Several
types of soluble factors (e.g., cytokines, chemokines, and
neurotrophic factors) that regulate pathophysiological
responses in nerve tissue are produced by reactive astrocytes
(Hamby and Sofroniew, 2010; Colangelo et al., 2014). Excess
production of cytokines and chemokines causes microglial
activation, infiltration of blood cells, neural apoptosis, and
breakdown of the blood–brain barrier, which exacerbates
neuroinflammation in the injured brain. However, reactive
astrocytes also produce neurotrophic factors, including
brain-derived neurotrophic factor (BDNF) and glial cell
line-derived neurotrophic factor (GDNF; Koyama et al.,
2003). These astrocyte-derived neurotrophic factors prevent
neuronal damage and stimulate neurogenesis, both of which
improve dysfunction of the injured brain. By releasing these
soluble factors, reactive astrocytes play prominent roles in
regulating pathophysiological responses in injured nerve
tissue, and suggest that modulation of astrocyte function
may be a promising target for neuroprotective drugs, which
can treat acute brain insults and neurodegenerative diseases.
The neuroprotective action of some drugs in modulating
astrocyte function have been observed in animal models
of brain ischemia, Parkinson’s disease, and amyotrophic
lateral sclerosis (ALS; Acarin et al., 2001; Cifra et al.,
2011; Tsuda et al., 2011; Carbone et al., 2012). There have
been some excellent review papers on the pharmacological
significance of astrocytes as a target for neuroprotective drugs
(Darlington, 2005; Hamby and Sofroniew, 2010; Colangelo et al.,
2014).
In addition to the release of gliotransmitters and neurotrophic
factors, studies have shown novel roles for astrocytic connexin-
43 (CX43) and aquaporin-4 (AQP4) in regulating nerve
function in both the pathological and physiological state.
CX43 is a main component of the astrocytic gap junction
(Koulakoff et al., 2008). Intracellular communication through
gap junctions enables sharing of cytosolic messengers and
excitability between adjacent cells (Scemes and Spray, 2012). In
astrocytes, CX43 expression is altered by brain injury (Rouach
et al., 2002), which affects the neuroprotective actions and
proliferation of astrocytes (Tabernero et al., 2006; Gangoso
et al., 2012; Theodoric et al., 2012). Therefore, modulation of
CX43-mediated gap junction communication may be a target
for neuroprotective drugs. Besides these pathophysiological
roles, gap junction activity stimulates the release of various
gliotransmitters. Stehberg et al. (2012) found that administration
of CX43 inhibitors to the rat basolateral amygdala prevents
fear memory consolidation, suggesting CX43 involvement in
physiological nerve function. Reduced CX43 expression was
observed in patients with major depressive disorder (MDD)
and alcohol dependence (Bernard et al., 2011; Miguel-Hidalgo
et al., 2014). From these findings, CX43 was proposed to
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be a target of drugs for mental disorders (Sun et al., 2012;
Morioka et al., 2014). AQP4 is a water channel highly expressed
in astrocytes. With regards the functional role of astrocytic
AQP4, its relationship to brain edema etiology has been
investigated (Manley et al., 2000). AQP4 is thought to be
involved in glial scar formation at injured nerve tissue and
in brain edema, because AQP4 inhibitors stimulate migration
of reactive astrocytes (Saadoun et al., 2005; Verkman et al.,
2006). Besides these pathological roles, recent studies have
suggested novel roles for astrocytic AQP4 in synaptic plasticity
and mental disorder pathogenesis. Skucas et al. (2011) found
that induction of long term-potentiation was attenuated in
the hippocampus of AQP4 null mice. In addition, deletion of
astrocytic AQP4 decreased morphine dependence and the anti-
depressant actions of fluoxetine (Kong et al., 2009; Yan et al.,
2013).
Because of the identification of these astrocytic functions,
the relationship between astrocytes and higher brain functions,
including regulation of emotion and mentality, has gained
greater attention. Many studies have since been performed to
determine the involvement of astrocyte dysfunction in mental
disorders (Figure 1), and have shown that astrocytes contribute
to the pathogenesis of some disorders.
Astrocytes in Mental Disorders
Schizophrenia
Schizophrenia is a mental disease that affects approximately 1%
of the population. Its symptoms are hallucination, delusions,
thought disorder, flat affect, social withdrawal, and cognitive
disorder. Genetic and environmental factors are involved in
schizophrenia, although its detailed mechanisms are not fully
understood. Drugs with antagonistic potency against dopamine
D2 receptors are widely used for treating schizophrenia.
These antagonists effectively manage the abnormal behavior,
and thus dysfunction of midbrain dopamine transmission is
generally accepted to underlie the symptoms of schizophrenia.
Further studies have shown involvement of L-Glu-mediated
excitatory transmission in schizophrenia pathogenesis (Coyle,
2006; Laruelle, 2014). In experimental animals, N-methyl-D-
aspartate (NMDA) receptor antagonists cause schizophrenia-
like behavioral abnormalities, accompanied by dopamine system
hyperactivation (Lipina et al., 2005; Karasawa et al., 2008; Bado
et al., 2011; Kawaura et al., 2014). Moreover, administration
of NMDA antagonists to schizophrenic patients aggravates
their symptoms (Javitt and Zukin, 1991; Krystal et al.,
1994), suggesting that inhibition of NMDA receptor-mediated
transmission facilitates induction of schizophrenia. NMDA
receptors have an allosteric site that regulates L-Glu-mediated
receptor activation. D-serine is a necessary co-factor for
NMDA receptor/channel gating, and enhances the excitatory
signal (Balu et al., 2012; Van Horn et al., 2013). The D-
Ser biosynthetic enzyme, serine racemase (SR), and D-Ser
degradation enzyme, D-amino acid oxidase (DAAO), are
both present in brain regions with high NMDA receptor
expression (Van Horn et al., 2013). Immunohistochemical
observations show that SR locates to astrocytes (Wolosker
et al., 1999; Panatier et al., 2006), while D-Ser release from
astrocytes is stimulated by excitatory amino acids (Martineau
et al., 2014), indicating that D-Ser serves as a gliotransmitter.
In schizophrenia patients, D-Ser levels are decreased in
cerebrospinal fluid (Hashimoto et al., 2003; Bendikov et al.,
2007), whereas DAAO protein and its activity are increased
in the hippocampus and cerebrum (Madeira et al., 2008;
Habl et al., 2009). Human genetic analysis shows that several
polymorphic variants of SR and DAAO are related to increased
risk of schizophrenia (Labrie et al., 2009; Caldinelli et al.,
2013). Concurrent with these observations, manipulation of
brain D-Ser levels induces schizophrenia-like behavior in
experimental animals. Basu et al. (2009) reported that genetic
deletion of SR causes hyperactivity and impaired memory
in mice, accompanied by altered NMDA responses. Further
observations of the SR null mouse found morphological and
neurochemical abnormalities in the brain, similar to those
in schizophrenia (Puhl et al., 2014). In contrast, DAAO
deletion reverses schizophrenia-like abnormal behavior in mice
with impaired NMDA receptor function (Labrie et al., 2010).
The effect of D-Ser and related drugs has been examined
in animal models of schizophrenia. Administration of D-
Ser, D-Ser reuptake inhibitors (ALX5407 and (R)-(N-[3-(4′-
fluorophenyl)-3-(4′-phenylphenoxy)propyl] sarcosine (NFPS))
and DAAO inhibitors ([4H-thieno [3, 2-b]pyrrole-5-carboxylic
acid] (compound 8), 5-chloro-benzo[d]isoxazol-3-ol (CBIO)
and AS057278) improve impaired pre-pulse inhibition and
cognitive defects induced by NMDA antagonists (Lipina et al.,
2005; Adage et al., 2008; Karasawa et al., 2008; Hashimoto
et al., 2009; Smith et al., 2009; Bado et al., 2011; Kawaura
et al., 2014). Therapeutic effects of D-Ser and glycine on
negative symptoms of schizophrenia patients have been reported,
and more effective drugs for enhancing NMDA receptor
signaling should be explored (Tuominen et al., 2005; Tsai
and Lin, 2010). Currently, atypical antipsychotics, which
improve both positive and negative symptoms, are used for
the treatment of schizophrenia. Some atypical antipsychotics
(clozapine, olanzapine, and risperidone), but not haloperidol,
enhance L-Glu transmission in the prefrontal cortex via
NMDA receptors (Ninan et al., 2003; Kargieman et al., 2007).
Recently, Tanahashi et al. (2012) showed that clozapine, but not
haloperidol, stimulates D-Ser release from astrocytes, suggesting
a novel mechanism of atypical antipsychotics in schizophrenia
treatment.
Mood Disorders (Major Depressive Disorder)
Among the mood disorders, morphological and functional
alterations of astrocytes are apparent in patients with MDD
(Sanacora and Banasr, 2013). Postmortem brain examination
of MDD patients shows decreased astrocyte cell number
and GFAP protein in the hippocampus (Stockmeier et al.,
2004), frontal cortex (Ongür et al., 1998; Cotter et al., 2002),
and amygdala (Hamidi et al., 2004). Decreased astrocyte cell
number and GFAP protein are reproduced in animal models
subjected to chronic unpredictable stress (Heine et al., 2004;
Czéh et al., 2006). Administration of L-α-aminoadipate (an
astrogliotoxin used as a tool to induce specific astrocytic
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FIGURE 1 | Astrocyte roles in the pathogenesis of mental disorders.
Pathological roles for astrocytes in induction and/or aggravation of
schizophrenia, depression, drug dependence, and fragile X syndrome
(FXS) are proposed. In patients with schizophrenia, D-Ser content in the
brain is decreased, while D-amino acid oxidase (DAAO) expression is
increased. These alterations in D-Ser may cause schizophrenia via
dysfunction of N-methyl-D-aspartate (NMDA) receptor-mediated signaling.
Decreased astrocyte cell number is found in patients with depression.
Reduction of astrocytes leads to leads to decreases in neurotrophic
factors, CX43 and excitatory amino acid transporters (EAATs). Decreases
in these astrocytic molecules cause disturbance of L-Glu turnover and
neurogenesis, which may aggravate depression. Many
dependence-producing drugs activate astrocytes. Production of
brain-derived neurotrophic factor (BDNF) by reactive astrocytes enhances
the rewarding effects of psychostimulants. fragile X mental retardation 1
(FMR1) is the gene responsible for FXS. Mutations in FMR1 cause
dysfunction of mGluR5 signaling in neurons and astrocytes, which impairs
normal brain development.
degeneration) into the rat prefrontal cortex causes depressive-
like behavior (Banasr and Duman, 2008). Based on these
findings, possible involvement of impaired astrocyte function
in the pathogenesis of depression has been investigated. While
therapeutic mechanisms of clinically used antidepressants
can be explained by the ‘‘monoamine hypothesis’’, L-Glu
transmission has also been considered as a therapeutic target
for depression. In rat social interaction and sucrose intake
tests, administration of L-Glu transport inhibitors leads
to depressive-like behavior (Lee et al., 2007; John et al.,
2012), suggesting that impaired L-Glu turnover between
astrocytes and neurons causes depression. As well as GFAP,
expressions of astrocyte-specific molecules (e.g., EAAT-1,
EAAT-2, and GS) are decreased in MDD, along with the
reduction in astrocyte cell number (Choudary et al., 2005).
As EAAT-1 and EAAT-2 are the main uptake pathways for
extracellular L-Glu into astrocytes, decreased EAAT-1 and
EAAT-2 expression may cause impaired L-Glu turnover
and result in depression. Involvement of impaired L-Glu
turnover in depression pathogenesis is supported by the
beneficial effect of riluzole in animal models of depression.
Riluzole, which is clinically used for ALS treatment, activates
L-Glu transporters (Fumagalli et al., 2008). Furthermore,
Banasr et al. (2010) found that riluzole reverses decreased
GFAP expression in the rat prefrontal cortex and improves
depressive-like behavior after chronic unpredicted stress.
Although the mechanisms underlying morphological and
functional alterations of astrocytes remain to be clarified, the
beneficial action of riluzole suggests that modulating L-Glu
turnover in astrocytes is a novel strategy for treatment of
depression.
Neuronal and glial cell genesis is not limited to the developing
brain and can occur in restricted areas of the adult brain,
mainly the hippocampus and sub-ventricular zone (SVZ).
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Many studies have attempted to show correlation between
the pathology of neurological disorders and deregulation of
cellular genesis in the adult brain. Reduced hippocampal
neurogenesis is implicated in the pathogenesis of depression,
and as a possible target of antidepressants (Santarelli et al.,
2003; Banasr and Duman, 2007). Moreover, recent animal
model studies implicate astrogliogenesis in depression
pathogenesis. Olfactory bulb dissection can induce depressive-
like behavioral changes in rats. Keilhoff et al. (2006) showed
that olfactory bulb dissection decreases neural precursor
proliferation in the hippocampus and SVZ, which can be
rescued by the antidepressant, imipramine. Similarly, chronic
social stress decreases astrocyte number and cell volume in
the rat hippocampus, which can be reversed by fluoxetine
(Czéh et al., 2006). In contrast, electroconvulsive seizures, an
effective treatment for severe depression, stimulates astrocyte
proliferation in the rat hippocampus and prefrontal cortex
(Ongür et al., 2007; Jansson et al., 2009). These findings support
the involvement of astrogliogenesis in the pathogenesis of
depression. Recently, Kong et al. (2014) found that deletion
of AQP4, a water channel protein expressed in astrocytes,
aggravates depressive-like behavior and is accompanied by a
further reduction in astrocyte cell number and hippocampal
neurogenesis. This suggests that astrocytic AQP4 may be a novel
target for antidepressants.
Increased production of neurotrophic factors is predicted
to be an effective treatment strategy for mood disorders,
because they promote neurogenesis, gliogenesis, and synaptic
structure remodeling. Levels of BDNF (Dwivedi et al., 2003),
GDNF (Otsuki et al., 2008; Zhang et al., 2008), and basic
fibroblast growth factor (bFGF; Evans et al., 2004) are decreased
in patients with depression, and relates to the reduced
hippocampal neurogenesis. Astrocytes are a main source of
these neurotrophic factors in pathological brain conditions
(Koyama et al., 2003). Administration of antidepressants
(e.g., desipramine, fluoxetine, mianserin, clomipramine, and
paroxetine) increases production of BDNF, GDNF, and bFGF
in the rat hippocampus (Mallei et al., 2002; Martínez-Turrillas
et al., 2005; Bachis et al., 2008; Liu et al., 2012), while in vitro
studies using cultured astrocytes treated with antidepressants
shows production of these neurotrophic factors (Hisaoka et al.,
2001; Allaman et al., 2011; Kittel-Schneider et al., 2012).
Thus, up-regulation of astrocytic trophic factor production
may partially underlie the therapeutic actions of presently used
antidepressants.
A relationship between CX43, a main component of astrocytic
gap junctions, and MDD has been suggested. Reduced brain
CX43 expression is observed in MDD patients (Bernard et al.,
2011; Miguel-Hidalgo et al., 2014). Inhibition of CX43-mediated
gap junction communication causes depressive-like behavior
in rodents (Sun et al., 2012). Besides neurotrophic factor
production, increased CX43 expression is proposed as a novel
mechanism for clinically used antidepressants. Sun et al. (2012)
found that fluoxetine and duloxetine increase CX43 expression
in rat brain. Moreover, amitriptyline increases CX43 expression
by a monoamine-independent mechanism in cultured astrocytes
(Morioka et al., 2014).
Drug Dependence
Repeated abuse of opiates, hypnotics, and psychostimulants
leads to drug dependence. It is known that drug-induced
alterations in synaptic strength in the mesocorticolimbic
dopamine system and modulatory glutamatergic neuronal
circuits, both part of the brain reward system, underlie
drug dependence (van Huijstee and Mansvelder, 2015).
Dependence-producing drugs commonly activate the main
pathway of the brain reward system, with dopamine released
from neurons in the ventral tegmental area (VTA) to the
nucleus accumbens (NAcc) and prefrontal cortex. Studies
on the mechanisms underlying drug dependence show a
possible role for astrocytes in modulating neurotransmission
in the brain reward system (Beardsley and Hauser, 2014).
Administration of amphetamine, methamphetamine, cocaine,
and morphine induces astrocyte activation and increases GFAP
expression in rodent brain (Hebert and O’Callaghan, 2000;
Fattore et al., 2002; Pubill et al., 2003; Alonso et al., 2007).
Although these astrocytic alterations are not necessarily a
common pathological feature shared by other drugs, these
observations facilitate examination of the mechanisms
underlying drug dependence in the context of astrocyte
function.
The L-Glu-mediated neural circuit from the prefrontal cortex
to NAcc plays an important regulatory role in the brain reward
system (van Huijstee and Mansvelder, 2015). Nakagawa et al.
(2005) examined the role of astrocytic L-Glu transporters in mice
by co-administrating MS-153, a glutamate transport activator,
with morphine, cocaine, or methamphetamine. They found
that activation of L-Glu transport attenuates conditioned place
preference (CPP) to these drugs. Administration of an adenoviral
vector carrying the glutamate transporter 1 (GLT1; EAAT-2)
gene into the NAcc also attenuated CPP induction by morphine
and methamphetamine (Fujio et al., 2005). Together, these
findings suggest there is inhibitory regulation from astrocytic
L-Glu transporters on the rewarding effect of dependence-
producing drugs.
Astrocyte-derived soluble factors have important roles in
regulating synaptic strength and plasticity. The effect of
astrocyte-derived factors on susceptibility to drug dependence
was examined using conditioned medium from cultured
astrocytes. Administration of astrocytic conditioned medium
into mouse NAcc caused sensitization of rewarding behavior
elicited by methamphetamine and morphine (Narita et al.,
2005, 2006), suggesting that astrocytes produce soluble factors
that enhance drug dependence. As astrocyte-derived factors
affect susceptibility of drug-dependence, the modulatory roles
of BDNF and GDNF on rewarding effects of psychostimulants
were examined (Ghitza et al., 2010). Enhancement of a rewarding
effect by BDNF was first shown by Horger et al. (1999), with
chronic BDNF administration into rat NAcc increasing CPP to
cocaine. Overexpression of exogenous BDNF and its receptor
(TrkB) in rat NAcc also increased CPP to cocaine (Bahi et al.,
2008), while mouse BDNF null mutants show reduced CPP
(Hall et al., 2003). Positive regulatory roles of BDNF were
also suggested from the rewarding effects of morphine and
amphetamine (Shen et al., 2006; Vargas-Perez et al., 2009). As
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had been predicted from animal experiments (Pu et al., 2006;
Hatami et al., 2007), a recent study showed that serum BDNF
levels in heroin-dependent patients are still higher than those of
control groups, even after drug withdrawal (Zhang et al., 2014).
The results from viral vector-mediated gene transfer experiments
in rodents (Vargas-Perez et al., 2014) propose that enhancement
of the BDNF signal in the VTA is related to drug withdrawal
aversion.
GDNF was originally discovered as a survival and
developmental factor for mesencephalon dopaminergic neurons,
and modulates nerve excitation in many brain regions, including
the VTA and NAcc (Carnicella and Ron, 2009). In contrast to
BDNF, GDNF serves as a negative reinforcement modulator
of the rewarding effects of psychostimulants. Administration
of GDNF into the rat VTA reduced CPP enhancement to
cocaine, while an anti-GDNF neutralizing antibody increased
it (Messer et al., 2000). Heterozygous GDNF deletion in
mice caused higher sensitivity in CPP and seeking behaviors
to methamphetamine than those of wild-type mice (Niwa
et al., 2007; Yan et al., 2007). Taking these observations into
consideration, a therapeutic effect for drugs enhancing GDNF
production in patients with psychostimulant dependence can
be expected. Cabergoline, a dopamine D2 agonist used for the
treatment of hyperprolactinemia and parkinsonism, increases
GDNF production in cultured astrocytes (Ohta et al., 2003,
2004) and rat VTA (Carnicella et al., 2009). Cabergoline-
induced GDNF production in rat VTA reduced reinforcement
of seeking and drinking behavior for alcohol (Carnicella et al.,
2009).
Neurodevelopmental Diseases
Dysplasia of nerve tissue during embryonic and postnatal
development underlies some neurological diseases with mental
retardation and cognitive defects. During development of the
embryonic brain, astrocytes support proliferation and migration
of neural precursors, neuronal differentiation, and synaptic
formation, although neurogenesis generally precedes maturation
of astrocytes from glial precursors (Freeman and Rowitch,
2013). Because of the important role of astrocytes in the
developing brain, investigations to explain the etiology of
neurodevelopmental diseases by astrocyte dysfunction have been
performed (Molofsky et al., 2012; Parpura et al., 2012). A
number of studies on two inherited developmental diseases with
mental retardation, Rett syndrome and FXS, show that mutations
in single genes are responsible for astrocyte dysfunction and
impaired brain development.
Rett syndrome, an X-linked neurological disease
characterized clinically by distinctive hand movements,
seizures, delayed brain and head growth, autism, and mental
retardation (Weng et al., 2011), is caused by mutations
in a transcription factor, methyl-CpG-binding protein
2 (MeCP2; Samaco and Neul, 2011). In studies using
MeCP2 null mutant mice as a model of Rett syndrome
(Chen et al., 2001), conditional MeCP2 expression in
postnatal neurons partly reversed behavioral abnormalities
(Giacometti et al., 2007; Guy et al., 2007), indicating
involvement of reduced neural MeCP2 in pathogenesis
of the model. In addition, reduced function of astrocytic
MeCP2 is also related to Rett syndrome pathogenesis.
In vitro experiments by Ballas et al. (2009) found that
hippocampal neurons cultured with MeCP2 deleted astrocytes
or their conditioned medium, failed to show normal
dendritic development. Impaired dendrite formation by
astrocytic MeCP2 occurs independent of the presence of
neural MeCP2, suggesting that dysregulation of astrocytic
soluble factors induced by MeCP2 deletion may relate to
induction of Rett syndrome-like phenotypes. Maezawa et al.
(2009) reported impairments in BDNF, interleukin-1β, and
interleukin-6 production in astrocytes from MeCP2 deleted
mutant mice.
FXS is a neurodevelopmental disease characterized by mental
retardation, autism, attention deficit, social anxiety, and specific
physical features. One of the genes responsible for FXS, fragile
X mental retardation 1 (FMR1), is on an X-linked chromosome.
Mutations in FMR1, with GCC expansions repeats in the
promoter region, decrease production of fragile X mental
retardation 1 protein (FMRP), which serves as a regulator of
local protein translation. Reduced FMRP activity in neurons
leads to dysregulation of synaptic protein expression and affects
dendrite formation (Bassell and Warren, 2008). FMR1 gene
deletion induces abnormal dendrite elongation and increases
spine density in the developing cerebral cortex (Comery et al.,
1997; Nimchinsky et al., 2001). Besides neuronal reduction,
reduced FMRP activity in astrocytes affects their function during
brain development (Jacobs and Doering, 2010; Jacobs et al.,
2010). The mechanisms by which reduced FMRP in astrocytes
induces abnormal dendrite development were investigated.
Yang et al. (2012) found that FMRP deletion increases
neurotrophin-3 production in astrocytes, which suggests that
excess neurotrophic actions underlie abnormalities in dendrite
development. The metabotropic glutamate receptor 5 (mGluR5)
is predicted to be a therapeutic drug target for FXS (Levenga
et al., 2011; Vinueza Veloz et al., 2012; Pop et al., 2014;
Scharf et al., 2015). Higashimori et al. (2013) proposed that
down-regulation of astrocytic mGluR5 and GLT-1 (EAAT-2)
by FMRP deletion may cause enhanced neuronal excitation
and lead to abnormal dendritic development in FXS mouse
models.
A Perspective of Astrocytes as a Drug
Target for Mental Disorders
Supported by considerable experimental evidence, the
importance of astrocytic functions during acute brain insults and
neurodegenerative diseases is established. Because modulation
of astrocytic function has several beneficial actions, astrocytes
are a promising target of neuroprotective drugs (Darlington,
2005; Hamby and Sofroniew, 2010; Colangelo et al., 2014).
Although neuronal degeneration is generally not observed,
disturbance of neurotransmission, abnormal brain development,
and remodeling of synaptic structure are found in the brains of
patients with mental disorders. Furthermore, morphological and
functional alterations of astrocytes are observed in patients with
certain mental disorders (Cotter et al., 2002; Stockmeier et al.,
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 July 2015 | Volume 9 | Article 261
Koyama Astrocytes in mental disorders
2004; Choudary et al., 2005; Madeira et al., 2008; Habl et al., 2009;
Beardsley and Hauser, 2014). Besides their role in neurogenesis
and synaptic formation during brain development, accumulating
evidence shows that astrocytes are an essential component
of synaptic transmission (Parpura et al., 2012; Araque et al.,
2014). In addition, involvement of astrocyte-specific molecules
such as CX43 and AQP4 in higher brain functions is reported
(Sun et al., 2012; Xiao and Hu, 2014). Prompted by these
findings, many studies have attempted to clarify the role of
astrocytes in mental disorders. As described in this review,
involvement of astrocytic dysfunction in the pathogenesis of
mental disorders is becoming increasingly studied (Figure 1).
Thus, the pharmacological significance of astrocytes as a novel
drug target for schizophrenia, mood disorders, drug dependence,
and neurodevelopmental disorders has been proposed (Table 1).
However, despite the accumulating evidence, compared with
neurons, there are still many astrocyte-related issues that need to
be clarified. These include classification of astrocyte sub-types,
differences in properties among brain regions, astrogliogenesis
in the developing and adult brain, and the associated regulatory
factors. Further investigation of these issues may lead to novel
drugs for the treatment for mental disorders.
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